Pangen Biotech Inc
222110
Company Profile
Business description
Pangen Biotech Inc is a biotechnology company. The company is engaged in the production and sales of biosimilar EPO drugs, contract manufacturing (CMO), and development technology transfer service (CDO) business for biopharmaceuticals, including non-clinical and clinical samples, and biopharmaceutical development business.
Contact
306 Sinwon-ro, Yeongtong-gu
4th floor, Yeongtong Innoplex 2nd building, Woncheon-dong
Gyeonggi-do
Suwon-si
KORT: +82 317339165
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
75
Stocks News & Analysis
stocks
Overvalued ASX share as market underestimates downside risks
Growth outlook solid, but upside more than priced in.
stocks
New production imminent for undervalued ASX gas play
LNG project receives first commissioning gas.
stocks
Going into earnings, is Tesla stock a buy, a sell, or fairly valued?
Awaiting more info on robotaxis and lower cost models, here’s what we think of Tesla stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,324.60 | 40.80 | 0.44% |
| CAC 40 | 8,206.07 | 17.48 | 0.21% |
| DAX 40 | 24,258.80 | 427.81 | 1.80% |
| Dow JONES (US) | 46,722.18 | 531.57 | 1.15% |
| FTSE 100 | 9,403.57 | 49.00 | 0.52% |
| HKSE | 25,858.83 | 611.73 | 2.42% |
| NASDAQ | 23,015.84 | 335.86 | 1.48% |
| Nikkei 225 | 49,185.50 | 1,603.35 | 3.37% |
| NZX 50 Index | 13,344.96 | 55.75 | 0.42% |
| S&P 500 | 6,739.38 | 75.37 | 1.13% |
| S&P/ASX 200 | 9,031.90 | 43.70 | 0.49% |
| SSE Composite Index | 3,863.89 | 24.14 | 0.63% |